Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.55 |
| ▸ | ACACA | Q13085 | 5/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081574 | 1.00 | ACACB (0.55) | ACACBACACADRD2KDM4EPKM | |
| SCHEMBL6641586 | 0.82 | KMT2A (0.60) | ACACBACACADRD2KMT2AATM | |
| SCHEMBL4354977 | 0.82 | KMT2A (0.60) | ACACBACACADRD2KMT2AATM | |
| SCHEMBL4346477 | 0.82 | KMT2A (0.60) | ACACBACACADRD2KMT2AATM | |
| SCHEMBL6641585 | 0.82 | KMT2A (0.60) | ACACBACACADRD2KMT2AATM | |
| SCHEMBL24364220 | 0.81 | DRD2 (0.44) | ACACBACACADRD2KMT2AATM | |
| SCHEMBL15318168 | 0.81 | ACACB (0.53) | ACACBACACADRD2KDM4EPKM | |
| SCHEMBL15318127 | 0.81 | ACACB (0.53) | ACACBACACADRD2KDM4EPKM | |
| SCHEMBL19909825 | 0.81 | ACACB (0.53) | ACACBACACADRD2KDM4EPKM | |
| SCHEMBL15318161 | 0.81 | ACACB (0.53) | ACACBACACADRD2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ACACB 3481/4885ACACA 2409/4885DRD2 287/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ACACB 3481/4885ACACA 2409/4885DRD2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.